Practice-changing study offers new option for tough breast cancer cases

A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1AEnEYd